Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novacept

This article was originally published in Start Up

Executive Summary

Gynecological Devices; Endometrial Ablation. Novacept feels its device for endometrial ablation will be easy for Ob/Gyns to use in an office setting. The device consistently tailors the ablation depth to the region of the uterus in which it is working,stops automatically once tissue has been properly ablated, and simply requires a physician to squeeze a trigger.

You may also be interested in...



Building Interventional Gynecology

Once a sluggish category for clinical innovation, gynecology is drawing new venture-backed companies eager to build upon the lead created by first-generation companies operating in minimally-invasive endometrial ablation and female sterilization. First generation companies had the difficult task of creating paths to early adopters of minimally invasive procedures. These now exist, and the clinical specialty appears to be also evolving in ways that encourage the growth of in-office procedures.

Novacept: A Patient Device Exit Strategy Succeeds

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.

Novacept: A Patient Device Exit Strategy Succeeds

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT036922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel